790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head a...

by Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Leora Horn, Frederic Triebel, Enric Carcereny, Margarita Majem, Bernard Doger, Julio Peguero, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone
Published 2020-11-01

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

by Joaquim Bosch-Barrera, Sara Verdura, José Carlos Ruffinelli, Enric Carcereny, Elia Sais, Elisabet Cuyàs, Ramon Palmero, Eugeni Lopez-Bonet, Alejandro Hernández-Martínez, Gloria Oliveras, Maria Buxó, Angel Izquierdo, Teresa Morán, Ernest Nadal, Javier A. Menendez
Published 2021-08-01

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.

by Fernando Franco, Enric Carcereny, Maria Guirado, Ana L Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel Del Barco, Oscar Juan, Francisco Aparisi, Jose L González-Larriba, Manuel Domine, Jose M Trigo, Manuel Cobo, Sara Cerezo, Julia Calzas, Bartomeu Massutí, Joaquim Bosch-Barrera, Paola García Coves, Marta Domènech, Mariano Provencio
Published 2021-01-01

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

by Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín Casal, Juana Oramas, Ana Laura Ortega, Mª. Angeles Sala, Airam Padilla, David Aguiar, Oscar Juan-Vidal, Remei Blanco, Edel del Barco, Natividad Martínez-Banaclocha, Gretel Benítez, Blanca de Vega, Ainhoa Hernández, Maria Saigi, Fernando Franco, Mariano Provencio
Published 2021-08-01

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

by James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD
Published 2021-02-01